Recent clinical trials indicate that sodium-glucose cotransporter-2(SGLT-2i) inhibitors reduce AF prevalence and complications in patients with diabetes mellitus (DM) and/or heart failure [6,7,8]. This evidence concerns the gene SLC5A2 and atrial fibrillation.